Cargando…
Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome
Atrial fibrillation (AF) and cardiometabolic syndrome (CMS) have been linked to inflammation and fibrosis. However, it is still unknown which inflammatory cytokines contribute to the pathogenesis of AF. Furthermore, cardiometabolic syndrome (CMS) risk factors such as obesity, hypertension, insulin r...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738559/ https://www.ncbi.nlm.nih.gov/pubmed/33344519 http://dx.doi.org/10.3389/fcvm.2020.613271 |
_version_ | 1783623143006404608 |
---|---|
author | Itani, Hana A. Jaffa, Miran A. Elias, Joseph Sabra, Mohammad Zakka, Patrick Ballout, Jad Bekdash, Amira Ibrahim, Rand Al Hariri, Moustafa Ghemrawi, Mirna Abi-Saleh, Bernard Khoury, Maurice Alam, Samir Mahfouz, Rami Jaffa, Ayad A. Azar, Sami T. Refaat, Marwan M. |
author_facet | Itani, Hana A. Jaffa, Miran A. Elias, Joseph Sabra, Mohammad Zakka, Patrick Ballout, Jad Bekdash, Amira Ibrahim, Rand Al Hariri, Moustafa Ghemrawi, Mirna Abi-Saleh, Bernard Khoury, Maurice Alam, Samir Mahfouz, Rami Jaffa, Ayad A. Azar, Sami T. Refaat, Marwan M. |
author_sort | Itani, Hana A. |
collection | PubMed |
description | Atrial fibrillation (AF) and cardiometabolic syndrome (CMS) have been linked to inflammation and fibrosis. However, it is still unknown which inflammatory cytokines contribute to the pathogenesis of AF. Furthermore, cardiometabolic syndrome (CMS) risk factors such as obesity, hypertension, insulin resistance/glucose intolerance are also associated with inflammation and increased level of cytokines and adipokines. We hypothesized that the inflammatory immune response is exacerbated in patients with both AF and CMS compared to either AF or CMS alone. We investigated inflammatory cytokines and fibrotic markers as well as cytokine genetic profiles in patients with lone AF and CMS. CMS, lone AF patients, patients with both lone AF and CMS, and control patients were recruited. Genetic polymorphisms in inflammatory and fibrotic markers were assessed. Serum levels of connective tissue growth factor (CTGF) were tested along with other inflammatory markers including platelet-to-lymphocyte ratio (PLR), monocyte-to-HDL ratio (MHR) in three groups of AF+CMS, AF, and CMS patients. There was a trend in the CTGF levels for statistical significance between the AF and AF+CMS group (P = 0.084). Genotyping showed high percentages of patients in all groups with high secretor genotypes of Interleukin-6 (IL-6) (P = 0.037). Genotyping of IFN-γ and IL-10 at high level showed an increase in expression in the AF + CMS group compared to AF and CMS alone suggesting an imbalance between the inflammatory and anti-inflammatory cytokines which is exacerbated by AF. Serum cytokine inflammatory cytokine levels showed that IL-4, IL-5, IL-10, IL-17F, and IL-22 were significant between the AF, AF+CMS, and CMS patients. Combination of both CMS and AF may be associated with a higher degree of inflammation than what is seen in either CMS or AF alone. Thus, the identification of a biomarker capable of identifying metabolic syndrome associated with disease will help in identification of a therapeutic target in treating this devastating disease. |
format | Online Article Text |
id | pubmed-7738559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77385592020-12-17 Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome Itani, Hana A. Jaffa, Miran A. Elias, Joseph Sabra, Mohammad Zakka, Patrick Ballout, Jad Bekdash, Amira Ibrahim, Rand Al Hariri, Moustafa Ghemrawi, Mirna Abi-Saleh, Bernard Khoury, Maurice Alam, Samir Mahfouz, Rami Jaffa, Ayad A. Azar, Sami T. Refaat, Marwan M. Front Cardiovasc Med Cardiovascular Medicine Atrial fibrillation (AF) and cardiometabolic syndrome (CMS) have been linked to inflammation and fibrosis. However, it is still unknown which inflammatory cytokines contribute to the pathogenesis of AF. Furthermore, cardiometabolic syndrome (CMS) risk factors such as obesity, hypertension, insulin resistance/glucose intolerance are also associated with inflammation and increased level of cytokines and adipokines. We hypothesized that the inflammatory immune response is exacerbated in patients with both AF and CMS compared to either AF or CMS alone. We investigated inflammatory cytokines and fibrotic markers as well as cytokine genetic profiles in patients with lone AF and CMS. CMS, lone AF patients, patients with both lone AF and CMS, and control patients were recruited. Genetic polymorphisms in inflammatory and fibrotic markers were assessed. Serum levels of connective tissue growth factor (CTGF) were tested along with other inflammatory markers including platelet-to-lymphocyte ratio (PLR), monocyte-to-HDL ratio (MHR) in three groups of AF+CMS, AF, and CMS patients. There was a trend in the CTGF levels for statistical significance between the AF and AF+CMS group (P = 0.084). Genotyping showed high percentages of patients in all groups with high secretor genotypes of Interleukin-6 (IL-6) (P = 0.037). Genotyping of IFN-γ and IL-10 at high level showed an increase in expression in the AF + CMS group compared to AF and CMS alone suggesting an imbalance between the inflammatory and anti-inflammatory cytokines which is exacerbated by AF. Serum cytokine inflammatory cytokine levels showed that IL-4, IL-5, IL-10, IL-17F, and IL-22 were significant between the AF, AF+CMS, and CMS patients. Combination of both CMS and AF may be associated with a higher degree of inflammation than what is seen in either CMS or AF alone. Thus, the identification of a biomarker capable of identifying metabolic syndrome associated with disease will help in identification of a therapeutic target in treating this devastating disease. Frontiers Media S.A. 2020-12-02 /pmc/articles/PMC7738559/ /pubmed/33344519 http://dx.doi.org/10.3389/fcvm.2020.613271 Text en Copyright © 2020 Itani, Jaffa, Elias, Sabra, Zakka, Ballout, Bekdash, Ibrahim, Al Hariri, Ghemrawi, Abi-Saleh, Khoury, Alam, Mahfouz, Jaffa, Azar and Refaat. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Itani, Hana A. Jaffa, Miran A. Elias, Joseph Sabra, Mohammad Zakka, Patrick Ballout, Jad Bekdash, Amira Ibrahim, Rand Al Hariri, Moustafa Ghemrawi, Mirna Abi-Saleh, Bernard Khoury, Maurice Alam, Samir Mahfouz, Rami Jaffa, Ayad A. Azar, Sami T. Refaat, Marwan M. Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome |
title | Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome |
title_full | Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome |
title_fullStr | Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome |
title_full_unstemmed | Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome |
title_short | Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome |
title_sort | genomic and proteomic study of the inflammatory pathway in patients with atrial fibrillation and cardiometabolic syndrome |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738559/ https://www.ncbi.nlm.nih.gov/pubmed/33344519 http://dx.doi.org/10.3389/fcvm.2020.613271 |
work_keys_str_mv | AT itanihanaa genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT jaffamirana genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT eliasjoseph genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT sabramohammad genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT zakkapatrick genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT balloutjad genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT bekdashamira genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT ibrahimrand genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT alharirimoustafa genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT ghemrawimirna genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT abisalehbernard genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT khourymaurice genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT alamsamir genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT mahfouzrami genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT jaffaayada genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT azarsamit genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT refaatmarwanm genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome |